This two-year open-label pilot clinical trial will evaluate the efficacy and safety of
romosozumab to treat bone loss in females with chronic spinal cord injury (SCI) and
osteoporosis (OP). Participants will receive monthly injections of romosozumab during the
first 12 months of the study. During the second year, participants will take oral alendronate
tablets on a weekly basis.